CONTEXT: Male hormonal contraception (MHC) combines hypothalamic-pituitary-gonadal axis blockade with exogenous androgen delivery to maintain extragonadal androgen end-organ effects. Concern exists that MHC may adversely impact prostate health. OBJECTIVE: The objective of the study was to determine the molecular impact of MHC on intraprostatic androgen concentrations and androgen action. DESIGN: This was a single-blind, randomized, placebo-controlled study. SETTING: The study was conducted at an academic medical center. PARTICIPANTS: 32 healthy men aged 25-55 yr participated in the study. INTERVENTION: Interventions included placebo, daily transdermal testosterone (T) (T-gel), T-gel + depomedroxyprogesterone acetate (T+DMPA), or T-gel + dutasteride daily (T+D) for 12 wk, and prostate biopsy during treatment wk 10. MAIN OUTCOME MEASURES: Serum and prostate androgen concentrations and prostate epithelial-cell gene expression were measured. RESULTS:Thirty men completed the study. Serum T levels were significantly increased in T-gel and T+D groups compared with baseline (P < 0.05) but were decreased with the addition of DMPA. Intraprostatic androgens were no different from placebo with T-gel treatment. Addition of DMPA to T resulted in 40% lower intraprostatic dihydrotestosterone (DHT) concentration (P = 0.0273 vs. placebo), whereas combining dutasteride with T resulted in a 90% decrease in intraprostatic DHT (P = 0.0012), 11-fold increased intraprostatic T (P = 0.0011), and 7-fold increased intraprostatic androstenedione (P = 0.0011). Significant differences in global or androgen-regulated prostate epithelial-cell gene expression were not observed. Androgen-regulated gene expression correlated with epithelial-cell androgen receptor and prostatic DHT in placebo, T-gel, and T+DMPA arms and with T and androstenedione levels in the T+D arm. CONCLUSIONS:MHC regimens do not markedly alter gene expression in benign prostate epithelium, suggesting they may not alter risk of prostate disease. Longer-term studies examining the impact of MHC on prostate health are needed.
RCT Entities:
CONTEXT: Male hormonal contraception (MHC) combines hypothalamic-pituitary-gonadal axis blockade with exogenous androgen delivery to maintain extragonadal androgen end-organ effects. Concern exists that MHC may adversely impact prostate health. OBJECTIVE: The objective of the study was to determine the molecular impact of MHC on intraprostatic androgen concentrations and androgen action. DESIGN: This was a single-blind, randomized, placebo-controlled study. SETTING: The study was conducted at an academic medical center. PARTICIPANTS: 32 healthy men aged 25-55 yr participated in the study. INTERVENTION: Interventions included placebo, daily transdermal testosterone (T) (T-gel), T-gel + depomedroxyprogesterone acetate (T+DMPA), or T-gel + dutasteride daily (T+D) for 12 wk, and prostate biopsy during treatment wk 10. MAIN OUTCOME MEASURES: Serum and prostate androgen concentrations and prostate epithelial-cell gene expression were measured. RESULTS: Thirty men completed the study. Serum T levels were significantly increased in T-gel and T+D groups compared with baseline (P < 0.05) but were decreased with the addition of DMPA. Intraprostatic androgens were no different from placebo with T-gel treatment. Addition of DMPA to T resulted in 40% lower intraprostatic dihydrotestosterone (DHT) concentration (P = 0.0273 vs. placebo), whereas combining dutasteride with T resulted in a 90% decrease in intraprostatic DHT (P = 0.0012), 11-fold increased intraprostatic T (P = 0.0011), and 7-fold increased intraprostatic androstenedione (P = 0.0011). Significant differences in global or androgen-regulated prostate epithelial-cell gene expression were not observed. Androgen-regulated gene expression correlated with epithelial-cell androgen receptor and prostatic DHT in placebo, T-gel, and T+DMPA arms and with T and androstenedione levels in the T+D arm. CONCLUSIONS: MHC regimens do not markedly alter gene expression in benign prostate epithelium, suggesting they may not alter risk of prostate disease. Longer-term studies examining the impact of MHC on prostate health are needed.
Authors: G Forti; R Salerno; G Moneti; S Zoppi; G Fiorelli; T Marinoni; A Natali; A Costantini; M Serio; L Martini Journal: J Clin Endocrinol Metab Date: 1989-02 Impact factor: 5.958
Authors: Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery Journal: Clin Cancer Res Date: 2011-08-01 Impact factor: 12.531
Authors: Leo Turner; Ann J Conway; Mark Jimenez; Peter Y Liu; Elise Forbes; Robert I McLachlan; David J Handelsman Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French Journal: Clin Cancer Res Date: 2004-01-15 Impact factor: 12.531
Authors: John K Amory; Nelson B Watts; Kirk A Easley; Paul R Sutton; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; J Lisa Tenover Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Arthi Thirumalai; Lori A Cooper; Katya B Rubinow; John K Amory; Daniel W Lin; Jonathan L Wright; Brett T Marck; Alvin M Matsumoto; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2016-05-12 Impact factor: 5.958
Authors: Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones Journal: J Mol Endocrinol Date: 2013-06-29 Impact factor: 5.098
Authors: Katarzyna Piotrowska; Christina Wang; Ronald S Swerdloff; Peter Y Liu Journal: Lancet Diabetes Endocrinol Date: 2016-02-23 Impact factor: 44.867